THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 85 filers reported holding THERAVANCE BIOPHARMA INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $38,000 | +46.2% | 4,542 | +58.2% | 0.00% | – |
Q1 2024 | $26,000 | -86.5% | 2,871 | -83.1% | 0.00% | – |
Q4 2023 | $192,000 | +131.3% | 17,015 | +77.9% | 0.00% | – |
Q3 2023 | $83,000 | +22.1% | 9,567 | +46.5% | 0.00% | – |
Q2 2023 | $68,000 | +28.3% | 6,532 | +33.8% | 0.00% | – |
Q1 2023 | $53,000 | -56.9% | 4,883 | -55.4% | 0.00% | – |
Q4 2022 | $123,000 | +83.6% | 10,953 | +65.7% | 0.00% | – |
Q3 2022 | $67,000 | +1575.0% | 6,610 | +1330.7% | 0.00% | – |
Q2 2022 | $4,000 | -96.8% | 462 | -96.5% | 0.00% | – |
Q1 2022 | $124,000 | -54.9% | 13,032 | -47.5% | 0.00% | – |
Q4 2021 | $275,000 | +75.2% | 24,836 | +17.6% | 0.00% | – |
Q3 2021 | $157,000 | -56.9% | 21,113 | -15.7% | 0.00% | – |
Q2 2021 | $364,000 | -16.5% | 25,056 | +17.4% | 0.00% | – |
Q1 2021 | $436,000 | +10.9% | 21,345 | -3.6% | 0.00% | – |
Q4 2020 | $393,000 | +16.6% | 22,136 | -2.7% | 0.00% | – |
Q3 2020 | $337,000 | -34.3% | 22,758 | -7.1% | 0.00% | – |
Q2 2020 | $513,000 | -11.6% | 24,486 | -2.4% | 0.00% | – |
Q1 2020 | $580,000 | -5.5% | 25,081 | +5.8% | 0.00% | – |
Q4 2019 | $614,000 | +60.7% | 23,716 | +21.0% | 0.00% | – |
Q3 2019 | $382,000 | +25.2% | 19,602 | +4.9% | 0.00% | – |
Q2 2019 | $305,000 | -26.9% | 18,692 | +1.7% | 0.00% | – |
Q1 2019 | $417,000 | -9.3% | 18,374 | +2.2% | 0.00% | – |
Q4 2018 | $460,000 | -24.5% | 17,978 | -3.5% | 0.00% | – |
Q3 2018 | $609,000 | +51.1% | 18,632 | +5.0% | 0.00% | – |
Q2 2018 | $403,000 | -0.2% | 17,750 | +6.5% | 0.00% | – |
Q1 2018 | $404,000 | +6.3% | 16,664 | +22.3% | 0.00% | – |
Q4 2017 | $380,000 | -29.0% | 13,622 | -12.9% | 0.00% | – |
Q3 2017 | $535,000 | +37.2% | 15,632 | +59.7% | 0.00% | – |
Q2 2017 | $390,000 | +1.3% | 9,789 | -6.4% | 0.00% | – |
Q1 2017 | $385,000 | -0.8% | 10,456 | -14.1% | 0.00% | – |
Q4 2016 | $388,000 | -50.7% | 12,179 | -43.9% | 0.00% | – |
Q3 2016 | $787,000 | +239.2% | 21,715 | +112.7% | 0.00% | – |
Q2 2016 | $232,000 | -88.6% | 10,210 | -90.6% | 0.00% | -100.0% |
Q1 2016 | $2,035,000 | +1083.1% | 108,287 | +932.6% | 0.00% | – |
Q4 2015 | $172,000 | +48.3% | 10,487 | -0.3% | 0.00% | – |
Q3 2015 | $116,000 | -15.3% | 10,515 | 0.0% | 0.00% | – |
Q2 2015 | $137,000 | +1270.0% | 10,515 | +1643.8% | 0.00% | – |
Q1 2015 | $10,000 | -44.4% | 603 | -50.8% | 0.00% | – |
Q4 2014 | $18,000 | -92.9% | 1,226 | -88.9% | 0.00% | – |
Q3 2014 | $255,000 | +844.4% | 11,094 | +1203.6% | 0.00% | – |
Q2 2014 | $27,000 | – | 851 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |